Multiple Myeloma is a type of blood cancer that develops in plasma cells — white blood cells responsible for producing ...

to treat a rare disease called AL amyloidosis. Affecting approximately 4,500 people annually in the U.S., AL amyloidosis can ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Legendary folk singer Sharda Sinha, known for her Chhath songs has died at the age of 72 years. The Padma Bhushan awardee was ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

Myeloma UK joined with patients and clinicians to challenge the decision, and today NICE confirmed that Elrexfio will now be ...

Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...